|
September 17, 2023
|
Enanta Pharmaceuticals to Present Data for EDP-323, its Oral, Once-Daily, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at the 9th ESWI Influenza Conference
|
|
September 7, 2023
|
Enanta Pharmaceuticals to Present Data for EDP-938, its Oral, Once-Daily, N-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2023
|
|
August 31, 2023
|
Enanta Pharmaceuticals to Participate in Investor Conferences in September
|
|
August 7, 2023
|
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter with Conference Call and Webcast Today at 4:30 p.m. ET
|
|
July 31, 2023
|
Enanta Pharmaceuticals to Host Conference Call on August 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal Third Quarter Ended June 30, 2023
|
|
June 20, 2023
|
Enanta Pharmaceuticals Announces Positive Data From a Phase 1 Clinical Study of EDP-323, an Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus
|
|
June 7, 2023
|
Enanta Pharmaceuticals Announces Data Presentation at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2023
|
|
May 31, 2023
|
Enanta Pharmaceuticals to Participate at Jefferies Global Healthcare Conference
|
|
May 9, 2023
|
Enanta Pharmaceuticals to Participate in Two Investor Conferences in May
|
|
May 8, 2023
|
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Conference Call and Webcast Today at 4:30 p.m. ET
|